Charlie Gibson
Charles has previously written for the MoneyWeek, giving readers his share tips regularly and covering other topics on the side such as stock markets and the economy. He has also written for The Business, Shares, Investors Chronicle and The Evening Standard, and Charles has presented on LBC and been a guest on BBC One and BBC World. Aside from his journalist background, Charles graduated as a chemist from the University of Oxford specialising in ligand gated ion channels.
Latest articles by Charlie Gibson
-
Could you profit from Pearson?
Features In an unpromising sector, educational publisher Pearson stands out, having announced its best-ever operating profit this week. Share tipster Charlie Gibson examines whether you should buy in.
By Charlie Gibson Published
Features -
Predators stalk Sainsbury's: should you buy in?
Features New bid rumours are swirling around Sainsbury's daily, so should investors take profits or hold on to their shares? Find out what share tipster Charlie Gibson thinks you should do now.
By Charlie Gibson Published
Features -
Should you buy into Rio Tinto now?
Features Rio Tinto is making an obscene amount of money, yet its stock is still cheap. Charlie Gibson looks into the story behind the share price and suggests what it means for investors.
By Charlie Gibson Published
Features -
Where to find value in pharmaceuticals
Features The glory days of the pharmaceutical giants may be over - but that doesn't mean they're on their deathbeds just yet. Charlie Gibson picks one blue-chip that's been sending out strong 'buy' signals.
By Charlie Gibson Published
Features -
Gamble of the week: miner to rise on Chinese zinc demand
Features This company has had a string of good news lately, and there could be more to come. Charlie Gibson explains why brave investors should think about investing in this zinc-gold miner.
By Charlie Gibson Published
Features -
Four ways to fat profits
Features There is no end in sight to the obesity epidemic which has gripped the US. That means an increase in related illnesses such as obesity, and a huge market for drug companies. Here are the best share tips from the US press.
By Charlie Gibson Published
Features -
Are Parkwood shares worth holding on to?
Features Despite its loss-making Healthcare division, Parkwood Holdings remains good value.
By Charlie Gibson Published
Features -
Common sense view on dividends is wrong
Features According to research by American academics, the commonly held assumption that low dividend payouts are a sign of future earnings growth is wrong. Using this philosophy, here are the best tips for potential investment targets on the London market.
By Charlie Gibson Published
Features -
Unique software puts 121 in pole position
Features Most ISPs were hit hard by the recent decision by Carphone Warehouse to offer free broadband. 121 Media, however, was a notable exception thanks to a unique piece of software it has developed.
By Charlie Gibson Published
Features -
Ten top tips for investing in diamond mining
Features Burgeoning demand from India and China means that the diamond mining industry is in the most positive situation for 30 years. Find out how you can make the most of the demand for diamonds.
By Charlie Gibson Published
Features -
Two great tips from the food sector
Features Overall demand for food tends to grow slowly - at about the same rate as the population. So any food company that can produce double-digit annual growth is definitely worth a second look.
By Charlie Gibson Published
Features -
A tasty prospect in meat processing
Features The meat processing business isn't the most attractive sector to invest in - but there's one company that looks to be a very tasty prosepct indeed...
By Charlie Gibson Published
Features -
Why the metals boom will run and run
Features Metal prices have kept rising in the face of disbelief from many commentators. But are there still opportunities out there for investors yet to get on board?
By Charlie Gibson Published
Features -
Making money from the Dogs of the Dow theory
Features One way for investors to play it safe is to follow the Dogs of the Dow theory, where investors buy the ten highest-yielding stocks in the Dow Jones Industrials Average.
By Charlie Gibson Published
Features -
How ethical investing can pay off, and unethical even more...
Features Does Socially Responsible Investing (SRI) mean having to trade profits for principles? Not necessarily, but is it as profitable as investing in the sinners?
By Charlie Gibson Published
Features -
Three tempting recovery plays
Features Unless you’re good at contrarian investing recovery shares should not form the core of your investment strategy. Yet there are occasions when markets overreact to a piece of news and this provides a profitable opportunity.
By Charlie Gibson Published
Features -
Has Buffett lost his touch?
Features After five years of “underwhelming” performance from Berkshire Hathaway has Warren Buffett finally lost his touch? Here are some alternative equities that could do more for your money.
By Charlie Gibson Published
Features -
Is property website Rightmove worth buying into?
Features Property website Rightmove.co.uk plans to float next month. But with shares looking expensive, is now the time to buy into the company?
By Charlie Gibson Published
Features -
Three ways to get exposure to eastern Europe
Features If you want to get exposure to eastern Europe, you don't have to invest in foreign stock markets. Here are just three London-listed investment vehicles that are full of eastern promise...
By Charlie Gibson Published
Features -
Sixteen prime targets for foreign takeovers
Features With UK-listed firms 18% to 44% cheaper than their US and Japanese counterparts, it's no wonder they are prime targets for foreign buyers. But which companies could be next?
By Charlie Gibson Published
Features -
How to buy into China through UK companies
Features There are many ways to invest in China, but one of the easiest is to buy into UK companies that have exposure to the country's rapid growth. Here are two stocks that look set to soar on demand from Chinese consumers.
By Charlie Gibson Published
Features -
Why it's time to switch from value to growth stocks
Features Value stocks have outperformed growth over the past 30 years, research suggests. But it could be time for growth to make a comeback...
By Charlie Gibson Published
Features -
AstraZeneca: a medicine worth taking?
Features Are AstraZeneca’s shares worth buying? Patent fears have hit the company, but investors would be well advised to look beyond the court room dramas.
By Charlie Gibson Published
Features -
Five cash shells for the adventurous
Features Investing in cash shells can be risky but new regulations are also creating an opportunity for the adventurous. Here are five that might be worth a look.
By Charlie Gibson Published
Features